Skip to main content

Table 1 Demographic, clinical, and laboratory data of Fabry disease patients

From: The impact of the COVID-19 pandemic on Fabry Disease Patients: an examination of Mood Status, Therapy Adherence, and COVID-19 infection

Characteristics

Patients (n = 67)

Age, years

37.0 ± 11.8

Male gender, %

47.8

Clinical manifestation of Fabry disease, %

 

 Skin findings

17.9

 Hearing loss

20.9

 Cornea verticillata

50.7

 Heart involvement

43.2

 Stroke

16.4

 Acroparesthesia

67.1

 Kidney involvement

65.7

Lyso-Gb3, ng/ml

10.7 ± 11.5

 Median (min–max)

6.3 (0.5–42.2)

Enzyme replacement therapy, %

86.6

 Agalsidase alfa

75.9

 Agalsidase beta

24.1

ERT duration, years

4.6 ± 3.7

  1. Data are expressed as mean ± SD for quantitative parameters and n (%) for nominal parameters unless otherwise stated
  2. ERT, enzyme replacement therapy